Integra LifeSciences (NASDAQ:IART) Price Target Cut to $19.00 by Analysts at Truist Financial

Integra LifeSciences (NASDAQ:IART - Free Report) had its target price decreased by Truist Financial from $26.00 to $19.00 in a report issued on Friday morning,Benzinga reports. Truist Financial currently has a hold rating on the life sciences company's stock.

Separately, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $22.71.

Integra LifeSciences Price Performance

Shares of IART traded down $0.31 during trading hours on Friday, reaching $15.77. 242,657 shares of the stock traded hands, compared to its average volume of 1,048,078. The company's 50-day moving average price is $21.88 and its two-hundred day moving average price is $22.29. The company has a market cap of $1.22 billion, a P/E ratio of -175.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. Integra LifeSciences has a 52-week low of $15.72 and a 52-week high of $32.66. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 earnings per share. On average, analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC boosted its holdings in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC grew its position in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $180,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.